Oncology Today with Dr Neil Love

Dr Christopher Lieu from the University of Colorado Cancer Center in Aurora, Colorado, discusses circulating tumor DNA-based molecular residual disease assessment and its current role in the management of colorectal cancer.NCPD information and select publications here.

Dr Hanny Al-Samkari, hematologist and clinical investigator at Massachusetts General Hospital, discusses novel ITP therapies from ASH 2025. He explains yonalimab’s BAFF-R mechanism, dosing, safety and effects on infections and allergies. He also covers rilzabrutinib’s BTK selectivity, LUNA-3 results, dosing challenges, and how these agents might be sequenced in practice.

Dr Sara M Tolaney, a Dana-Farber breast cancer researcher, and Dr Hope S Rugo, a City of Hope clinical trial expert, review antibody-drug conjugate trial data and treatment choices. They compare ADC options for HER2-low, HER2-positive, and triple-negative disease. They discuss sequencing, toxicity tradeoffs, brain metastasis management, ILD risk, and combining ADCs with immunotherapy.

Dr Anne Chiang, Yale medical oncologist focused on translational SCLC research, and Dr Hossein Borghaei, Fox Chase clinical investigator in lung cancer trials, discuss first-line immunotherapy plus chemotherapy, maintenance strategies including lurbinectedin and tarlatimab, real-world case decisions, biomarkers and molecular subtypes, and emerging trials shaping future front-line and maintenance approaches.

Dr Christopher Lieu, medical oncologist at the University of Colorado studying ctDNA in colorectal cancer. Dr Arvind Dasari, MD Anderson oncologist focused on MRD trials and translational research. Dr Stacey A Cohen, University of Washington oncologist expert in ctDNA biology. They discuss ctDNA/MRD biology, tumor‑informed vs tumor‑agnostic assays, surveillance strategies, trial landscapes, and practical uses for guiding imaging, surgery, and adjuvant decisions.

Dr Terence Friedlander, UCSF medical oncologist and bladder cancer investigator, discusses selection and sequencing of therapies and highlights key ESMO 2025 findings. He covers NIAGARA perioperative results, ADCs targeting HER2 and Trop-2, cross-resistance and payload concerns, T-DXd activity and ILD risk, and practical sequencing for frail or chemo-ineligible patients.

Dr Natalie S Callander from the University of Wisconsin Carbone Cancer Center in Madison and Dr Paul G Richardson from Dana-Farber Cancer Institute in Boston, Massachusetts, discuss the potential role of CELMoDs in the management of multiple myeloma, supporting clinical data and ongoing investigations.CME information and select publications here.

Dr Fern Anari from the Fox Chase Cancer Center in Philadelphia, Pennsylvania, and Dr Catherine Fahey from the Lineberger Comprehensive Cancer Center in Chapel Hill, North Carolina, present real patient cases on metastatic bladder cancer, with additional commentary from Dr Matthew Galsky from The Tisch Cancer Institute in New York, New York.CME information and select publications here.

Dr Ritu Salani from the David Geffen School of Medicine at UCLA in Los Angeles, California, reviews datasets from ESMO Congress 2025 relevant to the care of patients with gynecologic cancers.CME information and select publications here.

Dr Sagar Lonial from Winship Cancer Institute in Atlanta, Georgia, discusses recent clinical developments with BCMA-targeted therapy and investigational agents for relapsed/refractory multiple myeloma presented at ASH 2025.CME information and select publications here.